Official source Data mirrored from Centers for Medicare & Medicaid Services Open Payments · General Payments · CMS publication 2026-06-30 View official record

Covered recipient · General Payments record

MEGAN P COUVILLION

Allopathic & Osteopathic Physicians Dermatology

NPI
1760724157
CMS profile
2299247
Location
HOUSTON, TX

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

Saved items

Saved only in this browser. No account or alerts.

Filter and download payment records

General Payments · PY2023 · Entire year

$5,564.92

59 records · 0 disputed

Summary and payment records

  • CMS publication 2026-06-30
Read the payment records

“Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.”

— Centers for Medicare & Medicaid Services, Open Payments

A reported payment reflects a financial relationship a company disclosed. It does not indicate wrongdoing or a conflict of interest, and it says nothing about the quality of a provider's care.

These records are submitted to CMS and attested to by the reporting companies. CMS publishes them as reported; this site mirrors them without independent verification.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

How these totals are calculated
  • This total is the sum of the individual General Payments record amounts CMS published for the labeled program year(s); each record amount is used unmodified. The total itself is computed by this site. Nothing is estimated, weighted, or combined across categories.
  • General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
  • Methodology & Data — sourcing, labeling, and limitations.

Provider summaries generated . CMS updates this data on an annual cycle, and corrections or successful disputes made at CMS may not yet appear here. The official CMS record is authoritative for the current state. View the official CMS record ↗

By nature of payment

PY2023 · entire year · sorted by reported total

By paying entity

PY2023 · entire year · sorted by reported total

Page 2 of 2; records 51–59 of 59 matching records. This page contains 9 records (maximum 50), not the full filtered export. Use the CSV download for all matching records.

IndustryPayments · General Payments

MEGAN P COUVILLION

NPI 1760724157 · CMS profile ID 2299247

Allopathic & Osteopathic Physicians / Dermatology

HOUSTON, TX

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

General Payments, PY2023; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types

Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00

Page 2 of 2; records 51–59 of 59 matching records. This page contains 9 records (maximum 50), not the full filtered export.

Filtered page: https://industrypayments.org/provider/npi-1760724157?year=2023&recipient=provider&page=2#records-h

CMS source: https://openpaymentsdata.cms.gov/dataset/fb3a65aa-c901-4a38-a813-b04b00dfa2a9

Cite these filtered records

The citation includes this program year, filters, data edition, and page of results.

Plain
MEGAN P COUVILLION, NPI 1760724157, CMS profile ID 2299247. General Payments, PY2023; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 2 of 2; records 51–59 of 59 matching records. This page contains 9 records (maximum 50), not the full filtered export. IndustryPayments. https://industrypayments.org/provider/npi-1760724157?year=2023&recipient=provider&page=2#records-h. Source: https://openpaymentsdata.cms.gov/dataset/fb3a65aa-c901-4a38-a813-b04b00dfa2a9.
APA 7
IndustryPayments. (2026). MEGAN P COUVILLION, NPI 1760724157, CMS profile ID 2299247. General Payments, PY2023; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 2 of 2; records 51–59 of 59 matching records. This page contains 9 records (maximum 50), not the full filtered export. [Filtered data set page]. https://industrypayments.org/provider/npi-1760724157?year=2023&recipient=provider&page=2#records-h. Source: https://openpaymentsdata.cms.gov/dataset/fb3a65aa-c901-4a38-a813-b04b00dfa2a9.
Bluebook
MEGAN P COUVILLION, NPI 1760724157, CMS profile ID 2299247, IndustryPayments, General Payments, PY2023; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types (Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00). Page 2 of 2; records 51–59 of 59 matching records. This page contains 9 records (maximum 50), not the full filtered export. Source: https://openpaymentsdata.cms.gov/dataset/fb3a65aa-c901-4a38-a813-b04b00dfa2a9. https://industrypayments.org/provider/npi-1760724157?year=2023&recipient=provider&page=2#records-h.

Centers for Medicare & Medicaid Services, Open Payments

Citation formats are provided for reference; check the requirements of your publication.

Payment records · PY2023

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

General Payments · PY2023 · Physicians and non-physician practitioners · CMS publication 2026-06-30

59 matching records · $5,564.92 reported total · 0 disputed

Nature of payment: All payment types

Records imported here (UTC).

Link to these filtered records · CMS source dataset ↗

Download all 59 matching records (CSV)

CSV includes CMS record IDs, source and publication dates, the data edition, and a link to these filters. Formula-like text cells are prefixed with an apostrophe for spreadsheet safety.

Showing records 51–59 of 59.

Paying entityAmountDate Nature of paymentDispute statusPublication flagsPublished Record IDSource
Lilly USA, LLC $24.8503/23/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1031841757 CMS
AbbVie Inc. $131.0303/18/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 996530793 CMS
AbbVie Inc. $138.2502/08/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 996530789 CMS
Lilly USA, LLC $28.9502/06/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1031827241 CMS
AbbVie Inc. $17.3602/04/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 996530785 CMS
AbbVie Inc. $12.4202/01/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 996530781 CMS
AbbVie Inc. $26.0801/25/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 996530777 CMS
Galderma Laboratories, L.P. $21.2301/25/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1059689157 CMS
Journey Medical Corporation $14.4101/09/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1054355559 CMS

By program year

All program years on this page · sorted by year

Program yearAmountRecords
PY2019 $717.91 28
PY2020 $194.74 10
PY2021 $627.61 26
PY2022 $9,671.60 38
PY2023 $5,564.92 59
PY2024 $55,201.30 123
PY2025 $20,817.70 60

Source & provenance

Dataset
CMS Open Payments — General Payments
Publisher of source data
Centers for Medicare & Medicaid Services
CMS publication date
2026-06-30
Program years on this page
2019, 2020, 2021, 2022, 2023, 2024, 2025
Source files and profile matching
Generated from
OP_DTL_GNRL_PGYR2025_P06302026_06032026.csv

One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.

Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.

Research Payments

One row per program year and role, newest year first · amounts for the two roles are never added together

Program yearRoleAmountRecords
PY2025 Recipient $11,463.80 1
PY2025 Principal investigator $332,965.13 70
PY2024 Recipient $22,557.15 2
PY2024 Principal investigator $710,780.23 168
PY2023 Recipient $3,530.27 9
PY2023 Principal investigator $693,857.03 75
PY2022 Recipient $61.00 1
PY2022 Principal investigator $798,889.10 43
PY2021 Principal investigator $191,731.42 15
PY2020 Recipient $8,306.70 2
PY2020 Principal investigator $141,815.43 10
PY2019 Recipient $45,047.50 2
PY2019 Principal investigator $15,619.13 6

Research Payments are a separate CMS dataset, shown here separately and never added to General Payments. A research payment is often made to an institution, with this provider named as a principal investigator; each record states which role applies.

“If you are a physician who served as a principal investigator on a research study, you may see the payments associated with that research study listed under your name. This does not necessarily mean the payments are attributed to you. The dollar amount of the record corresponds to the total payment; the amounts are not attributed to each individual on the record.”

— Centers for Medicare & Medicaid Services, Open Payments Frequently Asked Questions, FAQ #12224

Research Payments records · PY2025

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

71 records in PY2025

Research Payments records (CSV)

RolePaying entityAmount DateRecipientStudy Dispute statusPublishedRecord ID
Principal investigator 1 ABBVIE INC. $7,562.52 12/31/2025 Non-covered Recipient Entity
PFLUGERVILLE DERMATOLOGY CLINICAL
BOTOX (onabotulinumtoxinA) for the Reduction of Masseter Muscle Prominence: A Phase 3, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study No dispute reported 06/30/2026 1202534933
Principal investigator 1 SUN PHARMACEUTICAL INDUSTRIES INC. $405.00 12/24/2025 Non-covered Recipient Entity
Austin Institute for Clinical Research, Inc
Extension Study to Evaluate Safety and Efficacy of CTP-543 in Adults With Alopecia Areata No dispute reported 06/30/2026 1246430896
Principal investigator 1 SUN PHARMACEUTICAL INDUSTRIES INC. $8,000.00 12/11/2025 Non-covered Recipient Entity
Pflugerville Derm Clinical Research
Study to Evaluate the Efficacy and Safety of Deuruxolitinib in Adolescents With Severe Alopecia Areata No dispute reported 06/30/2026 1252797068
Principal investigator 1 ABBVIE INC. $8,178.05 12/04/2025 Non-covered Recipient Entity
PFLUGERVILLE DERMATOLOGY CLINICAL
A Study to Assess Change in Disease Activity and Adverse Events of Oral Upadacitinib in Adult and Adolescent Participants With Moderate to Severe Hidradenitis Suppurativa Who Have Failed Anti-TNF Therapy (Step-Up HS) No dispute reported 06/30/2026 1202528540
Principal investigator 1 SUN PHARMACEUTICAL INDUSTRIES INC. $1,400.00 12/04/2025 Non-covered Recipient Entity
Austin Institute for Clinical Research, Inc
Extension Study to Evaluate Safety and Efficacy of CTP-543 in Adults With Alopecia Areata No dispute reported 06/30/2026 1246430894
Principal investigator 1 PFIZER INC. $305.76 11/04/2025 Non-covered Recipient Entity
Pflugerville Dermatology Clinical Research Center Inc
A PHASE 3 RANDOMIZED WITHDRAWAL AND DOSEUP TITRATION MULTICENTER EXTENSION STUDY INVESTIGATING THE SAFETY EFFICACY AND TOLERABILITY OF RITLECITINIB IN ADULT AND ADOLESCENT PARTICIPANTS WITH NONSEGMENTAL VITILIGO No dispute reported 06/30/2026 1228818804
Principal investigator 1 PFIZER INC. $2,015.50 10/31/2025 Non-covered Recipient Entity
Pflugerville Dermatology Clinical Research Center Inc
A PHASE 3 RANDOMIZED WITHDRAWAL AND DOSEUP TITRATION MULTICENTER EXTENSION STUDY INVESTIGATING THE SAFETY EFFICACY AND TOLERABILITY OF RITLECITINIB IN ADULT AND ADOLESCENT PARTICIPANTS WITH NONSEGMENTAL VITILIGO No dispute reported 06/30/2026 1228825693
Principal investigator 1 PFIZER INC. $1,845.40 10/21/2025 Non-covered Recipient Entity
Pflugerville Dermatology Clinical Research Center Inc
A PHASE 3 RANDOMIZED DOUBLEBLIND 52WEEK PLACEBOCONTROLLED MULTICENTER STUDY INVESTIGATING THE EFFICACY SAFETY AND TOLERABILITY OF RITLECITINIB IN ADULT AND ADOLESCENT PARTICIPANTS WITH NON SEGMENTAL VITILIGO No dispute reported 06/30/2026 1228825918
Principal investigator 1 PFIZER INC. $5,278.36 10/21/2025 Non-covered Recipient Entity
Pflugerville Dermatology Clinical Research Center Inc
A PHASE 3 RANDOMIZED WITHDRAWAL AND DOSEUP TITRATION MULTICENTER EXTENSION STUDY INVESTIGATING THE SAFETY EFFICACY AND TOLERABILITY OF RITLECITINIB IN ADULT AND ADOLESCENT PARTICIPANTS WITH NONSEGMENTAL VITILIGO No dispute reported 06/30/2026 1228826022
Principal investigator 1 ABBVIE INC. $7,900.80 10/15/2025 Non-covered Recipient Entity
PFLUGERVILLE DERMATOLOGY CLINICAL
BOTOX (onabotulinumtoxinA) for the Reduction of Masseter Muscle Prominence A Phase 3 Multicenter Randomized Double-Blind Placebo-Controlled Study No dispute reported 06/30/2026 1202517009
Principal investigator 1 ABBVIE INC. $7,043.32 10/09/2025 Non-covered Recipient Entity
PFLUGERVILLE DERMATOLOGY CLINICAL
A Study to Assess Change in Disease Activity and Adverse Events of Oral Upadacitinib in Adult and Adolescent Participants With Moderate to Severe Hidradenitis Suppurativa Who Have Failed Anti-TNF Therapy (Step-Up HS) No dispute reported 06/30/2026 1202515963
Principal investigator 1 SUN PHARMACEUTICAL INDUSTRIES INC. $1,674.00 10/08/2025 Non-covered Recipient Entity
Austin Institute for Clinical Research, Inc
Extension Study to Evaluate Safety and Efficacy of CTP-543 in Adults With Alopecia Areata No dispute reported 06/30/2026 1246430888
Principal investigator 1 ABBVIE INC. $210.00 10/02/2025 Non-covered Recipient Entity
PFLUGERVILLE DERMATOLOGY CLINICAL
BOTOX (onabotulinumtoxinA) for the Reduction of Masseter Muscle Prominence A Phase 3 Multicenter Randomized Double-Blind Placebo-Controlled Study No dispute reported 06/30/2026 1202513117
Principal investigator 1 ABBVIE INC. $210.00 10/02/2025 Non-covered Recipient Entity
PFLUGERVILLE DERMATOLOGY CLINICAL
BOTOX (onabotulinumtoxinA) for the Reduction of Masseter Muscle Prominence A Phase 3 Multicenter Randomized Double-Blind Placebo-Controlled Study No dispute reported 06/30/2026 1202513119
Principal investigator 1 ABBVIE INC. $6,390.75 09/18/2025 Non-covered Recipient Entity
PFLUGERVILLE DERMATOLOGY CLINICAL
BOTOX (onabotulinumtoxinA) for the Reduction of Masseter Muscle Prominence A Phase 3 Multicenter Randomized Double-Blind Placebo-Controlled Study No dispute reported 06/30/2026 1202511328
Principal investigator 1 ABBVIE INC. $4,304.88 09/03/2025 Non-covered Recipient Entity
PFLUGERVILLE DERMATOLOGY CLINICAL
A Study to Assess Change in Disease Activity and Adverse Events of Oral Upadacitinib in Adult and Adolescent Participants With Moderate to Severe Hidradenitis Suppurativa Who Have Failed Anti-TNF Therapy (Step-Up HS) No dispute reported 06/30/2026 1202507215
Principal investigator 1 PFIZER INC. $1,821.08 08/30/2025 Non-covered Recipient Entity
Pflugerville Dermatology Clinical Research Center Inc
A PHASE 3 RANDOMIZED WITHDRAWAL AND DOSEUP TITRATION MULTICENTER EXTENSION STUDY INVESTIGATING THE SAFETY EFFICACY AND TOLERABILITY OF RITLECITINIB IN ADULT AND ADOLESCENT PARTICIPANTS WITH NONSEGMENTAL VITILIGO No dispute reported 06/30/2026 1228841400
Principal investigator 1 SUN PHARMACEUTICAL INDUSTRIES INC. $1,066.50 08/20/2025 Non-covered Recipient Entity
Austin Institute for Clinical Research, Inc
Extension Study to Evaluate Safety and Efficacy of CTP-543 in Adults With Alopecia Areata No dispute reported 06/30/2026 1246430886
Principal investigator 1 ABBVIE INC. $16,453.00 08/14/2025 Non-covered Recipient Entity
PFLUGERVILLE DERMATOLOGY CLINICAL
BOTOX (onabotulinumtoxinA) for the Reduction of Masseter Muscle Prominence A Phase 3 Multicenter Randomized Double-Blind Placebo-Controlled Study No dispute reported 06/30/2026 1202504921
Principal investigator 1 ABBVIE INC. $126.00 08/11/2025 Non-covered Recipient Entity
PFLUGERVILLE DERMATOLOGY CLINICAL
BOTOX (onabotulinumtoxinA) for the Reduction of Masseter Muscle Prominence A Phase 3 Multicenter Randomized Double-Blind Placebo-Controlled Study No dispute reported 06/30/2026 1202504195
Principal investigator 1 ABBVIE INC. $368.80 08/11/2025 Non-covered Recipient Entity
PFLUGERVILLE DERMATOLOGY CLINICAL
BOTOX (onabotulinumtoxinA) for the Reduction of Masseter Muscle Prominence A Phase 3 Multicenter Randomized Double-Blind Placebo-Controlled Study No dispute reported 06/30/2026 1202504197
Principal investigator 1 Eli Lilly and Company $8,300.00 08/11/2025 Non-covered Recipient Entity
AUSTIN INSTITUTE FOR CLINICAL RESEARCH INC
A MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PHASE 3 STUDY TO EVALUATE THE EFFICACY AND SAFETY OF BARICITINIB IN ADULT PATIENTS WITH SEVERE ALOPECIA AREATA No dispute reported 06/30/2026 1187880873
Principal investigator 1 ABBVIE INC. $4,651.09 08/05/2025 Non-covered Recipient Entity
PFLUGERVILLE DERMATOLOGY CLINICAL
A Study to Assess Change in Disease Activity and Adverse Events of Oral Upadacitinib in Adult and Adolescent Participants With Moderate to Severe Hidradenitis Suppurativa Who Have Failed Anti-TNF Therapy (Step-Up HS) No dispute reported 06/30/2026 1202502148
Principal investigator 1 ABBVIE INC. $600.80 08/04/2025 Non-covered Recipient Entity
PFLUGERVILLE DERMATOLOGY CLINICAL
BOTOX (onabotulinumtoxinA) for the Reduction of Masseter Muscle Prominence A Phase 3 Multicenter Randomized Double-Blind Placebo-Controlled Study No dispute reported 06/30/2026 1202501026
Principal investigator 1 Janssen Research & Development, LLC $1,500.00 08/04/2025 Non-covered Recipient Entity
Austin Inst For Clinic Rsrch
Study of Guselkumab in Skin of Color Participants With Moderate-to-severe Plaque and/?or Scalp Psoriasis (VISIBLE) No dispute reported 06/30/2026 1175283773
Principal investigator 1 PFIZER INC. $2,639.18 07/29/2025 Non-covered Recipient Entity
Pflugerville Dermatology Clinical Research Center Inc
A PHASE 3 RANDOMIZED WITHDRAWAL AND DOSEUP TITRATION MULTICENTER EXTENSION STUDY INVESTIGATING THE SAFETY EFFICACY AND TOLERABILITY OF RITLECITINIB IN ADULT AND ADOLESCENT PARTICIPANTS WITH NONSEGMENTAL VITILIGO No dispute reported 06/30/2026 1228849345
Principal investigator 1 ABBVIE INC. $12,588.50 07/16/2025 Non-covered Recipient Entity
PFLUGERVILLE DERMATOLOGY CLINICAL
BOTOX (onabotulinumtoxinA) for the Reduction of Masseter Muscle Prominence A Phase 3 Multicenter Randomized Double-Blind Placebo-Controlled Study No dispute reported 06/30/2026 1202498388
Principal investigator 1 ABBVIE INC. $9,765.22 07/02/2025 Non-covered Recipient Entity
PFLUGERVILLE DERMATOLOGY CLINICAL
A Study to Assess Change in Disease Activity and Adverse Events of Oral Upadacitinib in Adult and Adolescent Participants With Moderate to Severe Hidradenitis Suppurativa Who Have Failed Anti-TNF Therapy (Step-Up HS) No dispute reported 06/30/2026 1202495279
Principal investigator 1 Janssen Research & Development, LLC $272.00 06/30/2025 Non-covered Recipient Entity
Austin Inst For Clinic Rsrch
Study of Guselkumab Versus Placebo for the Treatment of Low Body Surface Area Moderate Plaque Psoriasis (SPECTREM) No dispute reported 06/30/2026 1175283676
Principal investigator 1 Janssen Research & Development, LLC $2,104.00 06/30/2025 Non-covered Recipient Entity
Austin Inst For Clinic Rsrch
Study of Guselkumab Versus Placebo for the Treatment of Low Body Surface Area Moderate Plaque Psoriasis (SPECTREM) No dispute reported 06/30/2026 1175283716
Principal investigator 1 Janssen Research & Development, LLC $1,516.00 06/30/2025 Non-covered Recipient Entity
Austin Inst For Clinic Rsrch
Study of Guselkumab Versus Placebo for the Treatment of Low Body Surface Area Moderate Plaque Psoriasis (SPECTREM) No dispute reported 06/30/2026 1175283744
Principal investigator 1 PFIZER INC. $248.40 06/26/2025 Non-covered Recipient Entity
Pflugerville Dermatology Clinical Research Center Inc
A PHASE 3 RANDOMIZED WITHDRAWAL AND DOSEUP TITRATION MULTICENTER EXTENSION STUDY INVESTIGATING THE SAFETY EFFICACY AND TOLERABILITY OF RITLECITINIB IN ADULT AND ADOLESCENT PARTICIPANTS WITH NONSEGMENTAL VITILIGO No dispute reported 06/30/2026 1228851054
Principal investigator 1 Biofrontera Inc. $6.94 06/25/2025 Non-covered Recipient Entity
COSMETIC LASER AND DERMATOLOGY
STUDY TO EVALUATE THE SAFETY AND EFFICACY OFBF-200ALA(AMELUZ) AND BF-RHODOLED IN THE TREATMENT OF SUPERFICIALBASAL CELL CARCINOMA(SBCC) WITH PHOTODYNAMIC THERAPY (PDT). No dispute reported 06/30/2026 1208907484
Principal investigator 1 ABBVIE INC. $317.00 06/19/2025 Non-covered Recipient Entity
PFLUGERVILLE DERMATOLOGY CLINICAL
BOTOX (onabotulinumtoxinA) for the Reduction of Masseter Muscle Prominence A Phase 3 Multicenter Randomized Double-Blind Placebo-Controlled Study No dispute reported 06/30/2026 1202492421
Principal investigator 1 SUN PHARMACEUTICAL INDUSTRIES INC. $1,066.50 06/16/2025 Non-covered Recipient Entity
Austin Institute for Clinical Research, Inc
Extension Study to Evaluate Safety and Efficacy of CTP-543 in Adults With Alopecia Areata No dispute reported 06/30/2026 1246430882
Principal investigator 1 ABBVIE INC. $21,374.40 06/12/2025 Non-covered Recipient Entity
PFLUGERVILLE DERMATOLOGY CLINICAL
BOTOX (onabotulinumtoxinA) for the Reduction of Masseter Muscle Prominence A Phase 3 Multicenter Randomized Double-Blind Placebo-Controlled Study No dispute reported 06/30/2026 1202491285
Principal investigator 1 Janssen Research & Development, LLC $574.00 06/05/2025 Non-covered Recipient Entity
Austin Inst For Clinic Rsrch
Study of Guselkumab Versus Placebo for the Treatment of Low Body Surface Area Moderate Plaque Psoriasis (SPECTREM) No dispute reported 06/30/2026 1175283699
Principal investigator 1 ABBVIE INC. $3,111.95 06/03/2025 Non-covered Recipient Entity
PFLUGERVILLE DERMATOLOGY CLINICAL
A Study to Assess Change in Disease Activity and Adverse Events of Oral Upadacitinib in Adult and Adolescent Participants With Moderate to Severe Hidradenitis Suppurativa Who Have Failed Anti-TNF Therapy (Step-Up HS) No dispute reported 06/30/2026 1202489111
Recipient Nielsen BioSciences, Inc. $11,463.80 05/21/2025 Covered Recipient Physician CFW-3A No dispute reported 06/30/2026 1215093524
Principal investigator 1 ABBVIE INC. $15,192.30 05/16/2025 Non-covered Recipient Entity
PFLUGERVILLE DERMATOLOGY CLINICAL
BOTOX (onabotulinumtoxinA) for the Reduction of Masseter Muscle Prominence A Phase 3 Multicenter Randomized Double-Blind Placebo-Controlled Study No dispute reported 06/30/2026 1202485297
Principal investigator 1 SUN PHARMACEUTICAL INDUSTRIES INC. $533.25 05/15/2025 Non-covered Recipient Entity
Austin Institute for Clinical Research, Inc
Extension Study to Evaluate Safety and Efficacy of CTP-543 in Adults With Alopecia Areata No dispute reported 06/30/2026 1246430880
Principal investigator 1 PFIZER INC. $1,470.08 05/14/2025 Non-covered Recipient Entity
Pflugerville Dermatology Clinical Research Center Inc
A PHASE 3 RANDOMIZED WITHDRAWAL AND DOSEUP TITRATION MULTICENTER EXTENSION STUDY INVESTIGATING THE SAFETY EFFICACY AND TOLERABILITY OF RITLECITINIB IN ADULT AND ADOLESCENT PARTICIPANTS WITH NONSEGMENTAL VITILIGO No dispute reported 06/30/2026 1228858001
Principal investigator 1 ABBVIE INC. $3,939.60 05/06/2025 Non-covered Recipient Entity
PFLUGERVILLE DERMATOLOGY CLINICAL
A Study to Assess Change in Disease Activity and Adverse Events of Oral Upadacitinib in Adult and Adolescent Participants With Moderate to Severe Hidradenitis Suppurativa Who Have Failed Anti-TNF Therapy (Step-Up HS) No dispute reported 06/30/2026 1202481369
Principal investigator 1 PFIZER INC. $1,084.85 05/06/2025 Non-covered Recipient Entity
Pflugerville Dermatology Clinical Research Center Inc
A PHASE 3 RANDOMIZED WITHDRAWAL AND DOSEUP TITRATION MULTICENTER EXTENSION STUDY INVESTIGATING THE SAFETY EFFICACY AND TOLERABILITY OF RITLECITINIB IN ADULT AND ADOLESCENT PARTICIPANTS WITH NONSEGMENTAL VITILIGO No dispute reported 06/30/2026 1228857059
Principal investigator 1 Janssen Research & Development, LLC $2,381.00 04/28/2025 Non-covered Recipient Entity
Austin Inst For Clinic Rsrch
Study of Guselkumab Versus Placebo for the Treatment of Low Body Surface Area Moderate Plaque Psoriasis (SPECTREM) No dispute reported 06/30/2026 1175283736
Principal investigator 1 ABBVIE INC. $18,304.20 04/16/2025 Non-covered Recipient Entity
PFLUGERVILLE DERMATOLOGY CLINICAL
BOTOX (onabotulinumtoxinA) for the Reduction of Masseter Muscle Prominence A Phase 3 Multicenter Randomized Double-Blind Placebo-Controlled Study No dispute reported 06/30/2026 1202476990
Principal investigator 1 SUN PHARMACEUTICAL INDUSTRIES INC. $533.25 04/11/2025 Non-covered Recipient Entity
Austin Institute for Clinical Research, Inc
Extension Study to Evaluate Safety and Efficacy of CTP-543 in Adults With Alopecia Areata No dispute reported 06/30/2026 1246430878
Principal investigator 1 ABBVIE INC. $2,238.00 04/10/2025 Non-covered Recipient Entity
PFLUGERVILLE DERMATOLOGY CLINICAL
BOTOX (onabotulinumtoxinA) for the Reduction of Masseter Muscle Prominence A Phase 3 Multicenter Randomized Double-Blind Placebo-Controlled Study No dispute reported 06/30/2026 1202475815
Principal investigator 1 PFIZER INC. $826.61 04/08/2025 Non-covered Recipient Entity
Pflugerville Dermatology Clinical Research Center Inc
A PHASE 3 RANDOMIZED DOUBLEBLIND 52WEEK PLACEBOCONTROLLED MULTICENTER STUDY INVESTIGATING THE EFFICACY SAFETY AND TOLERABILITY OF RITLECITINIB IN ADULT AND ADOLESCENT PARTICIPANTS WITH NON SEGMENTAL VITILIGO No dispute reported 06/30/2026 1228859694
Principal investigator 1 ABBVIE INC. $6,495.56 04/03/2025 Non-covered Recipient Entity
PFLUGERVILLE DERMATOLOGY CLINICAL
A Study to Assess Change in Disease Activity and Adverse Events of Oral Upadacitinib in Adult and Adolescent Participants With Moderate to Severe Hidradenitis Suppurativa Who Have Failed Anti-TNF Therapy (Step-Up HS) No dispute reported 06/30/2026 1202471894
Principal investigator 1 SUN PHARMACEUTICAL INDUSTRIES INC. $533.25 03/19/2025 Non-covered Recipient Entity
Austin Institute for Clinical Research, Inc
Extension Study to Evaluate Safety and Efficacy of CTP-543 in Adults With Alopecia Areata No dispute reported 06/30/2026 1246430872
Principal investigator 1 PFIZER INC. $1,394.48 03/14/2025 Non-covered Recipient Entity
Pflugerville Dermatology Clinical Research Center Inc
A PHASE 3 RANDOMIZED WITHDRAWAL AND DOSEUP TITRATION MULTICENTER EXTENSION STUDY INVESTIGATING THE SAFETY EFFICACY AND TOLERABILITY OF RITLECITINIB IN ADULT AND ADOLESCENT PARTICIPANTS WITH NONSEGMENTAL VITILIGO No dispute reported 06/30/2026 1228862917
Principal investigator 1 ABBVIE INC. $23,085.70 03/13/2025 Non-covered Recipient Entity
PFLUGERVILLE DERMATOLOGY CLINICAL
M21-417 - BOTOX (onabotulinumtoxinA) for the Reduction of Masseter Muscle Prominence A Phase 3 Multicenter Randomized Double-Blind Placebo-Controlled Study No dispute reported 06/30/2026 1202463588
Principal investigator 1 Janssen Research & Development, LLC $404.00 03/10/2025 Non-covered Recipient Entity
Austin Inst For Clinic Rsrch
Study of Guselkumab in Skin of Color Participants With Moderate-to-severe Plaque and/?or Scalp Psoriasis (VISIBLE) No dispute reported 06/30/2026 1175283730
Principal investigator 1 Janssen Research & Development, LLC $400.00 03/10/2025 Non-covered Recipient Entity
Austin Inst For Clinic Rsrch
Study of Guselkumab in Skin of Color Participants With Moderate-to-severe Plaque and/?or Scalp Psoriasis (VISIBLE) No dispute reported 06/30/2026 1175283764
Principal investigator 1 ABBVIE INC. $7,479.88 03/06/2025 Non-covered Recipient Entity
PFLUGERVILLE DERMATOLOGY CLINICAL
M23-698 - A Study to Assess Change in Disease Activity and Adverse Events of Oral Upadacitinib in Adult and Adolescent Participants With Moderate to Severe Hidradenitis Suppurativa Who Have Failed Anti-TNF Therapy (Step-Up HS) No dispute reported 06/30/2026 1202458393
Principal investigator 1 PFIZER INC. $2,668.81 03/04/2025 Non-covered Recipient Entity
Pflugerville Dermatology Clinical Research Center Inc
A PHASE 3 RANDOMIZED WITHDRAWAL AND DOSEUP TITRATION MULTICENTER EXTENSION STUDY INVESTIGATING THE SAFETY EFFICACY AND TOLERABILITY OF RITLECITINIB IN ADULT AND ADOLESCENT PARTICIPANTS WITH NONSEGMENTAL VITILIGO No dispute reported 06/30/2026 1228862927
Principal investigator 1 Janssen Research & Development, LLC $3,537.00 02/27/2025 Non-covered Recipient Entity
Austin Inst For Clinic Rsrch
Study of Guselkumab Versus Placebo for the Treatment of Low Body Surface Area Moderate Plaque Psoriasis (SPECTREM) No dispute reported 06/30/2026 1175283685
Principal investigator 1 SUN PHARMACEUTICAL INDUSTRIES INC. $533.25 02/26/2025 Non-covered Recipient Entity
Austin Institute for Clinical Research, Inc
Extension Study to Evaluate Safety and Efficacy of CTP-543 in Adults With Alopecia Areata No dispute reported 06/30/2026 1246430870
Principal investigator 1 SUN PHARMACEUTICAL INDUSTRIES INC. $870.75 02/19/2025 Non-covered Recipient Entity
Austin Institute for Clinical Research, Inc
Extension Study to Evaluate Safety and Efficacy of CTP-543 in Adults With Alopecia Areata No dispute reported 06/30/2026 1246430868
Principal investigator 1 ABBVIE INC. $18,988.65 02/13/2025 Non-covered Recipient Entity
PFLUGERVILLE DERMATOLOGY CLINICAL
M21-417 - BOTOX (onabotulinumtoxinA) for the Reduction of Masseter Muscle Prominence A Phase 3 Multicenter Randomized Double-Blind Placebo-Controlled Study No dispute reported 06/30/2026 1202451501
Principal investigator 1 PFIZER INC. $1,821.08 02/06/2025 Non-covered Recipient Entity
Pflugerville Dermatology Clinical Research Center Inc
A PHASE 3 RANDOMIZED WITHDRAWAL AND DOSEUP TITRATION MULTICENTER EXTENSION STUDY INVESTIGATING THE SAFETY EFFICACY AND TOLERABILITY OF RITLECITINIB IN ADULT AND ADOLESCENT PARTICIPANTS WITH NONSEGMENTAL VITILIGO No dispute reported 06/30/2026 1228837679
Principal investigator 1 ABBVIE INC. $2,140.39 02/05/2025 Non-covered Recipient Entity
PFLUGERVILLE DERMATOLOGY CLINICAL
M23-698 - A Study to Assess Change in Disease Activity and Adverse Events of Oral Upadacitinib in Adult and Adolescent Participants With Moderate to Severe Hidradenitis Suppurativa Who Have Failed Anti-TNF Therapy (Step-Up HS) No dispute reported 06/30/2026 1202445645
Principal investigator 1 PFIZER INC. $920.00 02/03/2025 Non-covered Recipient Entity
AUSTIN INSTITUTE CLINICAL RESEARCH
A PHASE 3 RANDOMIZED DOUBLEBLIND 52WEEK PLACEBOCONTROLLED MULTICENTER STUDY INVESTIGATING THE EFFICACY SAFETY AND TOLERABILITY OF RITLECITINIB IN ADULT AND ADOLESCENT PARTICIPANTS WITH NON SEGMENTAL VITILIGO No dispute reported 06/30/2026 1228853733
Principal investigator 1 Eli Lilly and Company $360.00 01/31/2025 Non-covered Recipient Entity
AUSTIN INSTITUTE FOR CLINICAL RESEARCH INC
A STUDY OF LY3972406 IN ADULT PARTICIPANTS WITH MODERATE-TO-SEVERE PLAQUE PSORIASIS No dispute reported 06/30/2026 1187875995
Principal investigator 1 Janssen Research & Development, LLC $1,299.00 01/27/2025 Non-covered Recipient Entity
Austin Inst For Clinic Rsrch
Study of Guselkumab Versus Placebo for the Treatment of Low Body Surface Area Moderate Plaque Psoriasis (SPECTREM) No dispute reported 06/30/2026 1175283723
Principal investigator 1 PFIZER INC. $4,209.29 01/24/2025 Non-covered Recipient Entity
Pflugerville Dermatology Clinical Research Center Inc
A PHASE 3 RANDOMIZED WITHDRAWAL AND DOSEUP TITRATION MULTICENTER EXTENSION STUDY INVESTIGATING THE SAFETY EFFICACY AND TOLERABILITY OF RITLECITINIB IN ADULT AND ADOLESCENT PARTICIPANTS WITH NONSEGMENTAL VITILIGO No dispute reported 06/30/2026 1228863773
Principal investigator 1 SUN PHARMACEUTICAL INDUSTRIES INC. $1,066.50 01/22/2025 Non-covered Recipient Entity
Austin Institute for Clinical Research, Inc
Extension Study to Evaluate Safety and Efficacy of CTP-543 in Adults With Alopecia Areata No dispute reported 06/30/2026 1246430864
Principal investigator 1 Janssen Research & Development, LLC $6,186.00 01/20/2025 Non-covered Recipient Entity
Austin Inst For Clinic Rsrch
Study of Guselkumab in Skin of Color Participants With Moderate-to-severe Plaque and/?or Scalp Psoriasis (VISIBLE) No dispute reported 06/30/2026 1175283754
Principal investigator 1 ABBVIE INC. $25,529.70 01/16/2025 Non-covered Recipient Entity
PFLUGERVILLE DERMATOLOGY CLINICAL
M21-417 - BOTOX (onabotulinumtoxinA) for the Reduction of Masseter Muscle Prominence A Phase 3 Multicenter Randomized Double-Blind Placebo-Controlled Study No dispute reported 06/30/2026 1202439499
Principal investigator 1 Eli Lilly and Company $23,343.00 01/07/2025 Non-covered Recipient Entity
AUSTIN INSTITUTE FOR CLINICAL RESEARCH INC
A STUDY OF LY3972406 IN ADULT PARTICIPANTS WITH MODERATE-TO-SEVERE PLAQUE PSORIASIS No dispute reported 06/30/2026 1187875019